PTC Therapeutics (PTCT) reported $196.79 million in income for the quarter ended September 2024, representing a year-over-year enhance of 0.1%. EPS of -$1.39 for a similar interval compares to -$1.76 a yr in the past.
The reported income represents a shock of +13.41% over the Zacks Consensus Estimate of $173.51 million. With the consensus EPS estimate being -$1.54, the EPS shock was +9.74%.
Whereas traders intently watch year-over-year modifications in headline numbers — income and earnings — and the way they evaluate to Wall Avenue expectations to find out their subsequent plan of action, some key metrics at all times present a greater perception into an organization’s underlying efficiency.
Since these metrics play an important position in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps traders higher venture a inventory’s worth efficiency.
Right here is how PTC Therapeutics carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Avenue analysts:
- Revenues- Internet product income: $135.42 million versus the six-analyst common estimate of $111.28 million. The reported quantity represents a year-over-year change of -6%.
- Revenues- Royalty income: $61.37 million versus the six-analyst common estimate of $62.95 million. The reported quantity represents a year-over-year change of +22.3%.
- Revenues- Internet product revenue- Emflaza: $52 million in comparison with the $36.89 million common estimate based mostly on 4 analysts. The reported quantity represents a change of -22.4% yr over yr.
- Revenues- Internet product revenue- Translarna: $72 million versus $65.30 million estimated by 4 analysts on common. In comparison with the year-ago quarter, this quantity represents a +4.4% change.
View all Key Company Metrics for PTC Therapeutics here>>>
Shares of PTC Therapeutics have returned +8.1% over the previous month versus the Zacks S&P 500 composite’s +3.2% change. The inventory at the moment has a Zacks Rank #3 (Maintain), indicating that it might carry out consistent with the broader market within the close to time period.
Free At this time: Cashing in on The Future’s Brightest Vitality Supply
The demand for electrical energy is rising exponentially. On the similar time, we’re working to cut back our dependence on fossil fuels like oil and pure gasoline. Nuclear power is a perfect alternative.
Leaders from the US and 21 different international locations lately dedicated to TRIPLING the world’s nuclear power capacities. This aggressive transition might imply super income for nuclear-related shares – and traders who get in on the motion early sufficient.
Our pressing report, Atomic Alternative: Nuclear Vitality’s Comeback, explores the important thing gamers and applied sciences driving this chance, together with 3 standout shares poised to profit probably the most.
Download Atomic Opportunity: Nuclear Energy’s Comeback free today.
PTC Therapeutics, Inc. (PTCT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
